Dr. Klempner on the Unique Trial Design of KRYSTAL-1 in CRC

Sam Klempner, MD, member of the faculty, Oncology, Massachusetts General Hospital, Medicine, Harvard Medical School, discusses the design and eligibility criteria of the ongoing phase 1/2 KRYSTAL-1 trial (NCT03785249) in colorectal cancer (CRC).

The phase 1/2 trial aims to evaluate the safety and clinical activity of adagrasib (MRTX849) monotherapy in patients with advanced solid tumors harboring a KRAS G12C mutation, and to verify preclinical observations regarding the improved efficacy of adagrasib in combination with cetuximab (Erbitux) in this patient population. It features several cohorts specifically dedicated to CRC, as this disease type is an area of greater unmet need and interest in current drug development. The unique trial design allows investigators to efficiently evaluate this novel targeted therapy across multiple tumor types.

Similar to other recent targeted therapies, adagrasib was initially developed for patients in later lines of treatment, such as those who have progressed on standard treatments or do not have access to other available curative therapies, Klempner concludes. The trial is still currently recruiting.